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Abstract: Sepsis occurs frequently in the intensive care unit (ICU) and is a leading cause of admission, 
mortality, and cost. Treatment guidelines recommend early intervention, however positive blood culture 
results may take up to 48 hours. Insulin sensitivity (SI) is known to decrease with worsening condition 
and could thus be used to aid diagnosis. Some glycemic control protocols are able to accurately identify 
insulin sensitivity in real-time. 
Receiver operator characteristic (ROC) curves and cut-off SI values for sepsis diagnosis were calculated 
for real-time model-based insulin sensitivity from glycemic control data of 36 patients with sepsis. 
Patients were identified as having sepsis based on a clinically validated sepsis score (ss) of 2 or higher (ss 
= 0-4 for increasing severity). A clinical biomarker was calculated from patient clinical data to maximize 
the discrimination between cohorts. 
Insulin sensitivity as a sepsis biomarker for diagnosis of severe sepsis achieves a 50% sensitivity, 76% 
specificity, 4.8% PPV, and 98.3% NPV at a SI cut-off value of 0.00013 L*mU min-1. A clinical 
biomarker combining SI, temperature, heart rate, respiratory rate, blood pressure, and their respective 
hourly rates of change achieves 73% sensitivity, 80% specificity, 8.4% PPV, and 99.2% NPV. Thus, a 
clinical biomarker provides an effective real-time negative predictive diagnostic for severe sepsis. 
Examination of both inter- and intra-patient statistical distribution of this biomarker and sepsis score 
show potential avenues to improve the positive predictive value. 
Keywords: sepsis, insulin sensitivity, biomarker, diagnosis, receiver operator characteristic, glucose 
control, real-time clinical application. 
 
1. INTRODUCTION 
 
Sepsis presents a serious medical problem in the adult 
intensive care unit (ICU), with a 11-15% incidence of severe 
sepsis, 30-60% mortality rate, $22,100 USD average cost per 
case, $16.7 billion USD annual total cost, and 1.5% projected 
annual incidence increase (Angus et al., 2001). Sepsis 
treatment guidelines and patient management protocols 
recommend early goal-directed resuscitation of the septic 
patient during the first 6 hours after infection recognition 
(Dellinger et al., 2008). Currently, blood bacteria cultures are 
considered the gold standard for confirmation of infection. 
However, only 51% of sepsis cases are positively identified 
as cultured pathogens (Martin et al., 2003). 
Early interventions have been documented to reduce 
mortality from 46.5% to 30.5% (Rivers et al., 2001). In 
addition, a landmark clinical trial implementing a blood 
glucose control protocol resulted in a reduction in the 
incidence of sepsis (Van den Berghe et al., 2001). Currently 
available biomarkers, such as procalcitonin (PCT), provide 
sepsis diagnostic test results in 2-3 hours with commercially 
available kits, but to various levels of clinical accuracy 
(Carrigan et al., 2004). 
A clinically validated glucose-insulin model that is able to 
model insulin sensitivity (SI) in real-time has been used to 
develop blood glucose protocols for critically ill patients 
(Chase et al., 2007b, Lonergan et al., 2006). An integral-
based parameter identification method has been used to fit the 
data (Hann et al., 2005). The model-based SI has been 
observed to indicate the severity of illness and metabolic 
status, as well as being validated against euglycaemic clamp 
data (Lotz et al., 2006). Insulin sensitivity has also been 
previously documented as decreasing with worsening 
condition (Chambrier et al., 2000), and increasing with 
improvement (Chase et al., 2008, Langouche et al., 2007). 
This study aims to evaluate the relationship of modelled 
insulin sensitivity (Lin, 2006, Lonergan et al., 2006) and 
patient condition. In particular, this study examines using the 
modelled insulin sensitivity as a marker for real-time 
diagnosis and differentiation of Systemic Inflammatory 
Response Syndrome (SIRS) and sepsis in a cohort of adult 
ICU patients. It extends the work of Blakemore et al. (2008) 
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by increasing discrimination and utilizing additional clinical 
measurements. 
2. METHODS 
2.1  Physiological glucose-insulin model 
The physiological glucose-insulin model for clinically ill 
patients has one compartment for plasma glucose, two 
compartments for insulin kinetics, and a two-compartment 
dextrose absorption model. 
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In this model, G is the blood glucose level, I is the plasma 
insulin, and Q is the interstitial insulin. EGPmax is the 
theoretical maximum endogenous glucose production for a 
patient under no presence of glucose or insulin. Endogenous 
glucose production (EGP) is suppressed with increasing G 
and Q. Insulin independent glucose removal (excluding 
central nervous system uptake CNS) and the suppression of 
EGP from EGPmax with respect to G are represented with pG. 
In contrast, insulin mediated glucose removal and the 
suppression of EGP from EGPmax due to GLUT4 (which 
action is associated with the compounding effect of receptor-
binding insulin and blood glucose) is represented with SI. 
Insulin sensitivity (SI) is time varying and reflects evolving 
patient condition. Exogenous inputs are enteral dextrose 
infusion D(t) and insulin administration uex(t). Compartment 
P1 represents the stomach, and P2 represents the gut. 
Glucose appearance, P(t) from input D(t) is the flux of 
glucose transport out of the gut, P2. This flux is saturable, 
and the maximal out flux is Pmax. All other associated 
parameters are physiologically defined transport rates (n, k, 
d1, d2), saturation parameters (αG, αI), or volumes (VG, VI). 
2.2  Sepsis score (ss) criteria and analysis 
Sepsis is a systemic inflammatory response syndrome (SIRS) 
due to infection (Bone, 1992). In this study, sepsis is defined 
using the clinical classification score (ss) provided by the 
ACCP/SCCM guideline definitions (Levy et al., 2003). The 
criteria are defined in Tables 1-3, which include SIRS and the 
Sepsis-related Organ Failure Assessment (SOFA) score 
(Vincent et al., 1996). 
Table 1. SIRS criteria 
score Criteria 
+ 1 temperature < 36º C 
> 38º C 
+ 1 heart rate > 90/min 
+ 1 respiratory rate 
or PaCO2 
> 20/min 
< 32 mm Hg 
+ 1 white blood 
cell count 
< 4 x 109/L or > 12 x 109/L or 
presence of > 10% immature 
granulocytes 
 
Table 2. SOFA criteria 
score system criteria 
+ 1 cardiovascular 
MAPa or 
need for 
inotropes 
< 60 mm Hg 
+ 1 respiratory PaO2/FiO2 
<250 mm Hg/mm 
Hg 
<200 mm Hg/mm 
Hg with pneumonia 
+ 1 renal urine output < 0.5 ml/kg/h 
+ 1 blood platelets < 80 x 10
9/L or 50% 
drop in 3 days 
aMean arterial pressure 
 
Clinical data was gathered for n = 36 sepsis patients admitted 
to the medical ICU in Christchurch Hospital (Christchurch, 
New Zealand). Each patient was on the SPRINT blood 
glucose control protocol (Chase et al., 2008), providing 9208 
total patient hours of hourly modelled insulin sensitivity. The 
hourly SI was compared to SIRS and ss data. Note that each 
stay included periods of sepsis and without sepsis (ss = 0). 
These periods are differentiated by positive blood culture and 
SIRS ≥ 2, and thus ss ≥ 1. 
Table 3. Sepsis score (ss) criteria 
sepsis score SIRS > 2 
Infection 
during 
stay 
organ failure > 1 fluid resuscitation inotrope present 
high 
inotrope 
dosea 
0 normal       
1 sepsis X X     
2 severe sepsis X X X X   
3 septic shock X X X X X  
4 refractory septic shock X X X X X X 
aadrenaline or noradrenaline > 0.2 mg min-1 kg-1 
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Receiver Operator Characteristic (ROC) curves were used to 
examine the performance of SI as a diagnostic marker for 
sepsis. ROC curves effectively examine the ability of the 
biomarker to differentiate between populations. Sensitivity, 
specificity, positive predictive value (PPV), and negative 
predictive value (NPV) were also evaluated. ROC curves 
effectively examine the separation between normal and 
diseased populations in terms of probability density functions 
(PDF). Variablility of ss score from one hour to the next hour 
were also examined. 
Therefore, other clinical measurements were evaluated and 
combined with SI to create a biomarker that aims to maximise 
the PDF separation or discrimination in normal and septic 
groups. The biomarker was created as an hourly changing 
function based on hourly SI and clinical measurements. A 
linear recursive least square method was used to maximize 
the discrimination between populations. The specific goal 
was to provide discrimination for ss ≥ 2, where prior studies 
(Blakemore et al., 2008) only achieved it for ss ≥ 3. 
Achieving this goal for the lower ss = 2 value will provide a 
marker for a far larger group of patients. 
 
3. RESULTS AND DISCUSSION 
 
Table 4 shows the total hours at each sepsis score. The 
majority of the hours are at ss < 2. 
Table 4. Patient hours by sepsis score (ss) 
sepsis 
score (ss) 0 1 2 3 4 
patient 
hours 
4186 
(45.1%) 
4861 
(52.3%) 
91 
(1.0%) 
88 
(0.9%) 
60 
(0.6%) 
3.1  Insulin sensitivity (SI) and sepsis score (ss) 
Figure 1 shows a cumulative distribution function (CDF) plot 
of SI, for each ss group. SI is generally lower for more severe 
sepsis. However, the distinction between the septic (ss ≥ 1) 
and non-septic (ss = 0) groups is not clear. 
3.2  SI biomarker 
Figure 2 shows the ROC curve for SI as a sepsis biomarker. 
There is minimal discrimination between no sepsis (ss = 0) 
and a sepsis score of ss = 1. For ss ≥ 2, a SI cut-off value of 
0.00013 L*mU min-1 achieves a 50% sensitivity, 76% 
specificity, 4.8% PPV, and 98.3% NPV. 
Even though SI is generally lower at higher ss values, the 
distribution of SI for each ss group overlaps too much in 
Figure 1 and Figure 2 with the non septic group. Therefore, 
using SI level itself is not a completely effective sepsis 
biomarker. It should be noted that the improved modelling in 
this study has improved discrimination compared to prior 
results. 
 
 
Fig. 1. Cumulative distribution function (CDF) of insulin 
sensitivity (SI), grouped by sepsis score (ss). 
 
Fig. 2. Receiver operator characteristic (ROC) curve for SI 
biomarker, grouped by sepsis score (ss), with cutoff points 
(x). 
3.3 Clinical biomarker including SI 
Figure 3 shows the CDF of a biomarker combining SI and 
other clinical factors, for each ss group. The clinical 
measurements used in the biomarker include temperature, 
heart rate, respiratory rate, blood pressure, and their 
respective rates of change. SI is defined as in (1). The 
biomarker generally decreases with increasing sepsis 
severity. The discrimination between sepsis and non-septic 
groups is improved, as compared to Figure 1 using SI only as 
a diagnostic test. 
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Fig. 3. Cumulative distribution function (CDF) of the clinical 
biomarker, grouped by sepsis score (ss). 
Figure 4 shows the ROC curve for this biomarker. For ss ≥ 2, 
the biomarker achieves 73% sensitivity, 80% specificity, 
8.4% PPV, and 99.2% NPV. The addition of clinical 
measurements with SI significantly improved the diagnostic 
test performance for sepsis, as compared to using SI alone. In 
particular, the biomarker provides an effective negative 
predictive diagnosis for severe sepsis (ss = 2), which was not 
achieved previously. 
It is also clear comparing Figure 2 and Figure 4 that the 
discrimination between ss = 1 and ss ≥ 2 is now far wider. 
Note that ss = 1 is difficult to discriminate from ss = 0 and 
simple, clinical SIRS. Hence, as seen in Figure 2 and Figure 
4, its discrimination from ss = 0 is still marginal. 
 
Fig. 4. Receiver operator characteristic (ROC) curve for the 
clinical biomarker, grouped by sepsis score (ss), with cutoff 
points (x). 
Table 5 is a contingency table showing the biomarker 
diagnostic outcome for ss ≥ 2. There are 9208 total hours of 
patient data. This data is classified into four categories using 
sepsis score and biomarker test outcome: true positive (TP, n 
= 165), false positive (FP, n = 1802), false negative (FN, n = 
61), and true negative (TN, n = 7180). There are 8982 hours 
when ss < 2 and 226 hours when ss ≥ 2. Using the biomarker, 
7241 hours test negative and 1967 hours test positive. 
Table 5. Contingency table 
 
ss ≥ 2 
226 hours 
ss < 2 
8982 hours  
test positive 
1967 hours 
TP = 165 
(1.8%) 
FP = 1802 
(19.6%) 
PPV 
8.4% 
test negative 
7241 hours 
FN = 61 
(0.7%) 
TN = 7180 
(78%) 
NPV 
99.2% 
total 
9208 hours 
sensitivity 
73.0% 
specificity 
79.9%  
 
Note that these ratios also indicate the relative incidence and 
reflect clinical expectations with most sepsis not necessarily 
severe by hour. This last point is critical as most sepsis 
incidence is recorded by patients. By patient, the incidence of 
severe sepsis is 5-10% (Angus et al., 2001), which is 
reflected in this cohort. However, with rapid, aggressive 
treatment its incidence by hour is low. This low incidence is 
problematic in developing such a non-invasive and real-time 
clinical biomarker. 
Figure 5 provides a visual presentation of clinical sepsis score 
and the biomarker performance. Most of the patient hours are 
ss < 2 (TN + FP). Even though the biomarker correctly 
identifies the severity of sepsis 73% of the time when ss ≥ 2 
and 80% of the time when ss < 2, the PPV stays low because 
the ratio of TP to test positive is limited by the ratio between 
ss ≥ 2 to ss < 2. Again, the mathematics indicate that 
relatively low incidence by hour, as seen in the 8982 hours of 
ss < 2 and 4186 hours of ss = 0, hinders good PPV without 
nearly perfect specificity. 
 
Fig. 5. Histogram of clinical biomarker data, grouped by 
contingency results. 
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3.4 Sepsis time course 
Figure 6 effectively shows the probability of how ss changes 
from one hour to the next. The horizontal axis is the current 
hour ss and the vertical axis is the ss for the next hour. The 
majority of the patient data is when ss = 0 and ss = 1. 
Patients at ss = 1 tend to stay at ss = 1, and patients having ss 
= 0 tend to stay at ss = 0. Interestingly, when ss ≥ 2, the 
highest probability is moving to ss = 1 in the next hour. This 
set of results shows that if sepsis is detected at ss ≥ 2, current 
rapid and aggressive ICU treatments are usually very 
effective in reducing the severity of the inflammatory 
responses. 
 
Fig. 6. Scatter plot of clinical biomarker variation from hour 
to hour with respect to sepsis score (ss) (axis numbers = ss + 
biomarker/1000). 
3.5 Biomarker comparison 
The clinical informative values a biomarker may provide in 
sepsis are: detection of infection; diagnosis of SIRS severity 
and infection progression; and patient treatment guidance, 
responsiveness, and prognosis. One such investigated 
biomarker is procalcitonin (PCT), which was first found 
elevated in sepsis in 1993 (Assicot et al. 1993). PCT is a 
precursor of the hormone calcitonin, synthesized by thyroid C 
cells, but in sepsis has an extra-tyroidal origin. Upon 
intravenous injection of endotoxin from E. coli in healthy 
volunteers, serum PCT becomes detectable after 4 hours, 
maintaining a plateau through 8 to 24 hours, following an 
increase of proinflammatory cytokines (Dandona 1994). 
PCT can be measured from serum plasma by commercially 
available immunoluminometric assay kits such as LUMItest 
PCT (Brahms, Berlin, Germany) and Kryptor PCT (Brahms, 
Hennigsdorf, Germany). The use of PCT has been approved 
by the FDA “in conjunction with other laboratory findings 
and clinical assessments to aid in the risk assessment of 
critically ill patients on their first day of ICU admission for 
progression to severe sepsis and septic shock”. 
The reported diagnostic power of PCT from 25 studies using 
PCT (2,966 patients) as a diagnostic marker of sepsis, severe 
sepsis, or septic shock in the adult ICU or after surgery or 
multiple trauma, compared with nonseptic SIRS is sensitivity 
ranging from 42% to 97% or even 100% and specificity 
ranging from 48% to 100% (Uzzan et al. 2006). Optimal 
cutoff values for PCT, determined from ROC curves, ranged 
from 0.6 to 5 ng/mL. 
PCT is generally only assessed once a day and thus cannot 
provide real-time detection. In contrast, the biomarker 
presented in this study is a real-time marker. In addition, all 
of these studies had some form of pre-screening for sepsis 
and/or SIRS biasing the sensitivity or specificity. The overall 
results reported are no better, and often worse, than those 
reported here. 
Traditionally, diagnostic test results are based on a cut-off 
point. This method effectively treats all patients as a single, 
generic person with one clear cut-off point that distinguishes 
between normal and abnormal states. However, recent 
medical treatments have been moving towards patient 
customisation – tailoring treatments to patient needs (Chase 
et al., 2007a). Although this study has so far provided a 
sepsis biomarker that has a cut-off value which can 
differentiate ss ≥ 2 from ss < 2 most of the time, this 
biomarker is also a time-varying value. As with most clinical 
measurements, this biomarker would have both inter- and 
intra-patient statistical distribution. 
3.6 Future work 
It is therefore of interest to further investigate how this 
biomarker changes through time for patients, and how much 
variability there is between patients. A means of normalizing 
patients and likely changes using stochastic models would 
improve biomarker performance. An observational study and 
follow-up of a biomarker for sepsis diagnosis in the ICU 
would provide the data needed for that analysis. Finally, the 
statistical model of a biomarker, like the one developed in 
this paper, may be more useful clinically by providing a 
probability analysis of disease progression in real-time. 
 
4. CONCLUSIONS 
 
Insulin sensitivity as a sepsis biomarker for diagnosis of 
severe sepsis achieves a 50% sensitivity, 76% specificity, 
4.8% PPV, and 98.3% NPV at a SI cut-off value of 0.00013 
L*mU min-1. A discriminating threshold was not found 
between the ss = 0 and ss = 1 cohorts due to patient 
population overlap. A clinical biomarker combining SI, 
temperature, heart rate, respiratory rate, blood pressure, and 
the respective rate of change achieves 73% sensitivity, 80% 
specificity, 8.4% PPV, and 99.2% NPV, and thus an effective 
negative predictive diagnosis for severe sepsis. 
PPV performance is low because the ratio of TP to test 
positive is limited by the ratio of hours between ss ≥ 2 to ss < 
2. The majority of patient hours were ss < 2. However, 
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clinical biomarker data may provide patient-specific 
diagnosis, and effectively show the probability of sepsis time 
course from hour to hour. Real-time results may aid in the 
treatment and management of sepsis in the ICU. Future work 
includes an observational study and follow-up of a biomarker 
for sepsis diagnosis in the ICU. 
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